Published in J Immunol on June 01, 2005
Microclusters of inhibitory killer immunoglobulin-like receptor signaling at natural killer cell immunological synapses. J Cell Biol (2006) 1.42
Granzyme B degradation by autophagy decreases tumor cell susceptibility to natural killer-mediated lysis under hypoxia. Proc Natl Acad Sci U S A (2013) 0.96
Missing self, NK cells, and The White Album. J Immunol (2005) 0.92
Natural Killer Cell Immunomodulation: Targeting Activating, Inhibitory, and Co-stimulatory Receptor Signaling for Cancer Immunotherapy. Front Immunol (2015) 0.85
Fusion proteins of Hsp70 with tumor-associated antigen acting as a potent tumor vaccine and the C-terminal peptide-binding domain of Hsp70 being essential in inducing antigen-independent anti-tumor response in vivo. Cell Stress Chaperones (2006) 0.78
Immune profiling and cancer post transplantation. World J Nephrol (2015) 0.77
Aiming to immune elimination of ovarian cancer stem cells. World J Stem Cells (2013) 0.75
Rat embryonic fibroblasts immortalized by MRPS18-2 protein are target for NK-cells. Oncotarget (2017) 0.75
Heat-shock proteins as activators of the innate immune system. Trends Immunol (2002) 2.96
Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res (2010) 2.74
Pharmacological activation of p53 triggers anticancer innate immune response through induction of ULBP2. Cell Cycle (2011) 2.43
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
The strength of inhibitory input during education quantitatively tunes the functional responsiveness of individual natural killer cells. Blood (2008) 2.24
NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J Clin Invest (2009) 2.08
Circulating heat shock protein and heat shock protein antibody levels in established hypertension. J Hypertens (2002) 2.05
Regulatory T cells in cancer. Adv Cancer Res (2010) 2.02
NK cell education: not an on-off switch but a tunable rheostat. Trends Immunol (2009) 2.00
Naturally occurring regulatory T cells show reduced sensitivity toward oxidative stress-induced cell death. Blood (2008) 1.96
A role for MHC class I molecules in synaptic plasticity and regeneration of neurons after axotomy. Proc Natl Acad Sci U S A (2004) 1.78
Natural killer cell education in mice with single or multiple major histocompatibility complex class I molecules. J Exp Med (2005) 1.76
A signal peptide derived from hsp60 binds HLA-E and interferes with CD94/NKG2A recognition. J Exp Med (2002) 1.67
LIR-1 expression on lymphocytes, and cytomegalovirus disease in lung-transplant recipients. Lancet (2003) 1.59
DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. Cancer Res (2007) 1.45
Multipotent mesenchymal stromal cells express FoxP3: a marker for the immunosuppressive capacity? J Immunother (2011) 1.44
Pillars article: Association of class I major histocompatibility heavy and light chains induced by viral peptides. Nature 1989. 340: 443-448. J Immunol (2007) 1.40
Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells. J Immunol (2009) 1.38
Camouflage and sabotage: tumor escape from the immune system. Cancer Immunol Immunother (2011) 1.36
On the armament and appearances of human myeloid-derived suppressor cells. Clin Immunol (2012) 1.35
Pivotal role of KARAP/DAP12 adaptor molecule in the natural killer cell-mediated resistance to murine cytomegalovirus infection. J Exp Med (2002) 1.33
Gut microbiota accelerate tumor growth via c-jun and STAT3 phosphorylation in APCMin/+ mice. Carcinogenesis (2012) 1.31
DAP12 signaling directly augments proproliferative cytokine stimulation of NK cells during viral infections. J Immunol (2006) 1.26
IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. J Clin Invest (2002) 1.24
The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cells. Blood (2011) 1.24
A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growth. Proc Natl Acad Sci U S A (2006) 1.22
Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer. Clin Cancer Res (2002) 1.18
Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas. Proc Natl Acad Sci U S A (2008) 1.18
Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. Int J Cancer (2004) 1.17
Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms. Cancer Res (2013) 1.17
Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells. Int Immunol (2003) 1.17
Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants. Nat Med (2006) 1.17
Increased thioredoxin-1 production in human naturally occurring regulatory T cells confers enhanced tolerance to oxidative stress. Blood (2010) 1.14
NK cell function and antibodies mediating ADCC in HIV-1-infected viremic and controller patients. Viral Immunol (2011) 1.13
Is survivin the potential Achilles' heel of cancer? Adv Cancer Res (2011) 1.12
DAP12 signaling regulates plasmacytoid dendritic cell homeostasis and down-modulates their function during viral infection. J Immunol (2006) 1.11
Human NK cells selective targeting of colon cancer-initiating cells: a role for natural cytotoxicity receptors and MHC class I molecules. J Immunol (2013) 1.11
Skewing of the NK cell repertoire by MHC class I via quantitatively controlled enrichment and contraction of specific Ly49 subsets. J Immunol (2012) 1.11
HLA expression in uveal melanoma: there is no rule without some exception. Hum Immunol (2002) 1.08
Distinct phenotype and function of NK cells in the pancreas of nonobese diabetic mice. J Immunol (2010) 1.08
Loss or mismatch of MHC class I is sufficient to trigger NK cell-mediated rejection of resting lymphocytes in vivo - role of KARAP/DAP12-dependent and -independent pathways. Eur J Immunol (2004) 1.06
Mature dendritic cells are protected from Fas/CD95-mediated apoptosis by upregulation of Bcl-X(L). Cancer Immunol Immunother (2002) 1.05
Autocrine secretion of Fas ligand shields tumor cells from Fas-mediated killing by cytotoxic lymphocytes. Cancer Res (2004) 1.04
T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2. Int J Cancer (2010) 1.03
Activating and inhibitory receptors on synovial fluid natural killer cells of arthritis patients: role of CD94/NKG2A in control of cytokine secretion. Immunology (2007) 1.03
A structural basis for LCMV immune evasion: subversion of H-2D(b) and H-2K(b) presentation of gp33 revealed by comparative crystal structure.Analyses. Immunity (2002) 1.02
In vivo tumor cell rejection induced by NK cell inhibitory receptor blockade: maintained tolerance to normal cells even in the presence of IL-2. Eur J Immunol (2010) 1.01
Functional gap junctions facilitate melanoma antigen transfer and cross-presentation between human dendritic cells. J Immunol (2007) 1.01
HER2/HER3 signaling regulates NK cell-mediated cytotoxicity via MHC class I chain-related molecule A and B expression in human breast cancer cell lines. J Immunol (2012) 1.00
HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice. Cancer Immunol Immunother (2008) 1.00
Classical major histocompatibility complex class I molecules in motoneurons: new actors at the neuromuscular junction. J Neurosci (2009) 0.99
Increased proportion of CD56bright natural killer cells in active and inactive systemic lupus erythematosus. Immunology (2008) 0.98
Intratumoral forkhead box P3-positive regulatory T cells predict poor survival in cyclooxygenase-2-positive uveal melanoma. Cancer (2010) 0.98
Transduction with the antioxidant enzyme catalase protects human T cells against oxidative stress. J Immunol (2008) 0.98
Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production. Cancer Immunol Res (2013) 0.97
Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines. Int J Cancer (2011) 0.97
Frequent loss of HLA-A2 expression in metastasizing ovarian carcinomas associated with genomic haplotype loss and HLA-A2-restricted HER-2/neu-specific immunity. Cancer Res (2006) 0.97
A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors. Cancer Res (2005) 0.97
Immunization with heat shock protein 70 from methylcholanthrene-induced sarcomas induces tumor protection correlating with in vitro T cell responses. Cancer Immunol Immunother (2002) 0.97
Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial. J Transl Med (2010) 0.97
The MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancer. J Immunol (2013) 0.96
Expression and prognostic significance of iNOS in uveal melanoma. Int J Cancer (2010) 0.96
Natural killer cell tolerance persists despite significant reduction of self MHC class I on normal target cells in mice. PLoS One (2010) 0.96
Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma. Cancer Immunol Immunother (2008) 0.94
Immune monitoring in a phase 1 trial of a PSA DNA vaccine in patients with hormone-refractory prostate cancer. J Immunother (2005) 0.94
Alterations in the cellular immune compartment of patients treated with third-party mesenchymal stromal cells following allogeneic hematopoietic stem cell transplantation. Stem Cells (2013) 0.93
Oxidative stress and lymphocyte persistence: implications in immunotherapy. Adv Cancer Res (2009) 0.93
Probing natural killer cell education by Ly49 receptor expression analysis and computational modelling in single MHC class I mice. PLoS One (2009) 0.93
Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expression. Oncoimmunology (2012) 0.93
Tumor-dependent increase of serum amino acid levels in breast cancer patients has diagnostic potential and correlates with molecular tumor subtypes. J Transl Med (2013) 0.92
DAI (DLM-1/ZBP1) as a genetic adjuvant for DNA vaccines that promotes effective antitumor CTL immunity. Mol Ther (2010) 0.91
The CD16- CD56(bright) NK cell subset is resistant to reactive oxygen species produced by activated granulocytes and has higher antioxidative capacity than the CD16+ CD56(dim) subset. J Immunol (2007) 0.91
CD4+ T cell-mediated HER-2/neu-specific tumor rejection in the absence of B cells. Int J Cancer (2004) 0.90
A synthetic peptide homologous to functional domain of human IL-10 down-regulates expression of MHC class I and Transporter associated with Antigen Processing 1/2 in human melanoma cells. J Immunol (2004) 0.90
Intradermal DNA electroporation induces survivin-specific CTLs, suppresses angiogenesis and confers protection against mouse melanoma. Cancer Immunol Immunother (2009) 0.89
Marked enhancement of the antigen-specific immune response by combining plasmid DNA-based immunization with a Schiff base-forming drug. Infect Immun (2002) 0.89
A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma. Cancer Immunol Immunother (2014) 0.88
Modulation of the tumor cell phenotype by IFN-gamma results in resistance of uveal melanoma cells to granule-mediated lysis by cytotoxic lymphocytes. J Immunol (2008) 0.88
Melanocortin 1 receptor is expressed by uveal malignant melanoma and can be considered a new target for diagnosis and immunotherapy. Invest Ophthalmol Vis Sci (2007) 0.88
Retinoids act as multistep modulators of the major histocompatibility class I presentation pathway and sensitize neuroblastomas to cytotoxic lymphocytes. Cancer Res (2003) 0.86
Spontaneous mutations in the human CMV HLA class I homologue UL18 affect its binding to the inhibitory receptor LIR-1/ILT2/CD85j. Eur J Immunol (2006) 0.86
A structural basis for CD8+ T cell-dependent recognition of non-homologous peptide ligands: implications for molecular mimicry in autoreactivity. J Biol Chem (2005) 0.85
IFN-gamma regulates Fas ligand expression in human CD4+ T lymphocytes and controls their anti-mycobacterial cytotoxic functions. Eur J Immunol (2007) 0.85
Antibody-dependent natural killer cell-mediated cytotoxicity engendered by a kinase-inactive human HER2 adenovirus-based vaccination mediates resistance to breast tumors. Cancer Res (2010) 0.85
Altered distribution of natural killer cell subsets identified by CD56, CD27 and CD70 in primary and chronic human immunodeficiency virus-1 infection. Immunology (2007) 0.85
Improved immunogenicity of an immunodominant epitope of the HER-2/neu protooncogene by alterations of MHC contact residues. J Immunol (2004) 0.85
Comparative expression profiling of distinct T cell subsets undergoing oxidative stress. PLoS One (2012) 0.85
Increased expression of leukocyte Ig-like receptor-1 and activating role of UL18 in the response to cytomegalovirus infection. J Immunol (2007) 0.84
Natural killer cell inhibitory receptor expression in humans and mice: a closer look. Front Immunol (2013) 0.84
Increased cell-mediated immune responses in patients with recurrent herpes simplex virus type 2 meningitis. Clin Vaccine Immunol (2011) 0.84
A short-term dietary supplementation of high doses of vitamin E increases T helper 1 cytokine production in patients with advanced colorectal cancer. Clin Cancer Res (2002) 0.84
HER-2/neu-mediated down-regulation of biglycan associated with altered growth properties. J Biol Chem (2012) 0.84
Structural basis of the differential stability and receptor specificity of H-2Db in complex with murine versus human beta2-microglobulin. J Mol Biol (2005) 0.83
Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer. Cancer Immunol Immunother (2012) 0.82
Nuclear HER3 is associated with favorable overall survival in uveal melanoma. Int J Cancer (2011) 0.82
Expression patterns of the immunomodulatory enzyme arginase 1 in blood, lymph nodes and tumor tissue of early-stage breast cancer patients. Oncoimmunology (2012) 0.82
NK cell inhibitory receptor Ly-49C residues involved in MHC class I binding. J Immunol (2002) 0.82
HLA-dependent tumour development: a role for tumour associate macrophages? J Transl Med (2013) 0.82
Interferon-gamma renders tumors that express low levels of Her-2/neu sensitive to cytotoxic T cells. Cancer Immunol Immunother (2005) 0.81